ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 07/01/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 06/30/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 06/30/22
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read WhyBenzinga • 06/27/22
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid TumorsBusiness Wire • 06/27/22
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/09/22
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBusiness Wire • 02/28/22
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid TumorsPRNewsWire • 01/20/22
Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma MultiformePRNewsWire • 12/15/21
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate CancerPRNewsWire • 12/13/21
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast CancerPRNewsWire • 12/08/21
Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 11/10/21
Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 08/12/21
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 05/17/21